American Association for Cancer Research
Browse
crc-22-0478-s12.png (260.54 kB)

Supplementary Figure S10 from LNS8801 inhibits Acute Myeloid Leukemia by inducing the production of reactive oxygen species and activating the endoplasmic reticulum stress pathway

Download (260.54 kB)
figure
posted on 2023-07-19, 13:00 authored by Inyoung Lee, Miriam Doepner, Jillian S Weissenrieder, Ariana D Majer, Sophia Mercado, Angela Estell, Christopher A Natale, Pamela J Sung, J. Kevin Foskett, Martin Carroll, Todd W Ridky

Supplementary Figure S10. LNS8801 induces cell death independently of the classical secreted death ligands (A) Time course western blot of U937 cells treated with 250nM LNS8801. (B) Annexin V staining flow analysis of U937 cells treated with either 20ng/mL TNF⍺, 10ug/mL TNFR1 antibody, or 250nM LNS8801. Cells were incubated for 72 hours. 3 replicates were used per condition. (C) Annexin V staining flow analysis of U937 cells treated with LNS8801-treated U937 conditioned media. Cells were incubated in conditioned media for 72 hours. 3 replicates were used per condition. One-way ANOVA was used for statistical analysis (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001).

History

ARTICLE ABSTRACT

Despite recent therapeutic advances, the 5-year survival rate for adults with acute myeloid leukemia (AML) is poor and standard of care chemotherapy is associated with significant toxicity, highlighting the need for new therapeutic approaches. Recent work from our group and others established that the G protein-coupled estrogen receptor (GPER) is tumor suppressive in melanoma and other solid tumors. We performed a preliminary screen of human cancer cell lines from multiple malignancies and found that LNS8801, a synthetic pharmacologic agonist of GPER currently in early phase clinical trials, promoted apoptosis in human AML cells. Using human AML cell lines and primary cells, we show that LNS8801 inhibits human AML in preclinical in vitro models, while not affecting normal mononuclear cells. Although GPER is broadly expressed in normal and malignant myeloid cells, this cancer specific LNS8801-induced inhibition appeared to be independent of GPER signaling. LNS8801 induced AML cell death primarily through a caspase dependent apoptosis pathway. This was independent of secreted classical death receptor ligands, and instead required induction of reactive oxygen species (ROS) and activation of endoplasmic reticulum (ER) stress response pathways including IRE1a. These studies demonstrate a novel activity of LNS8801 in AML cells and show that targeting ER stress with LNS8801 may be a useful therapeutic approach for AML.